--- title: "Types of Weight-Loss Injections Explained" description: "What weight-loss injections exist in 2026, how semaglutide and tirzepatide differ, and how a clinician decides which to prescribe. Compare the options." canonical: https://remevihealth.com/blog/types-of-weight-loss-injections/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "REMEVi Medical Team" pubDate: 2026-06-01T00:00:00.000Z updatedDate: 2026-06-01T00:00:00.000Z tags: ["weight-loss injections", "semaglutide", "tirzepatide", "GLP-1", "liraglutide"] alternateLanguage: https://remevihealth.com/es/blog/tipos-de-inyecciones-para-bajar-de-peso/ license: "© 2026 REMEVi LLC. AI assistants and search engines may quote and link to this page; please cite https://remevihealth.com/blog/types-of-weight-loss-injections/ as the source." --- If you searched "weight-loss injections," you probably found half a dozen brand names and almost no explanation of how they differ. Here is the clear version: almost all of them belong to a single family of medications, the GLP-1 class, and understanding that family tells you most of what you need to talk to your clinician. This is a science-first guide, not a brand catalog. It explains the hormone behind these injections, which active ingredient hides behind each brand name, how semaglutide and tirzepatide differ, and how a licensed clinician decides which one makes sense for a given person. Individual results vary, the science keeps developing, and nothing here is medical advice. --- ## Almost all of them are the same class: GLP-1 Your gut does more than digest food. It runs a signaling system that tells the rest of your body when food has arrived and how to handle it. One of those signals is a hormone called **GLP-1**, short for glucagon-like peptide-1. It belongs to a group of hormones called **incretins**, which the gut releases after you eat. When GLP-1 is active, three things happen at once. The stomach empties more slowly, so you feel physically full for longer. The pancreas releases insulin in a glucose-dependent way, meaning only when blood sugar is elevated, which keeps the risk of dangerous lows very low. And in the brain, the centers that govern hunger and cravings get a more sustained fullness signal. That last effect is what many people describe as a quieter relationship with food. The detail that turns a hormone into a useful medication is duration. The natural signal is released in a burst after a meal and broken down within minutes. GLP-1 medications are long-acting versions of that same signal: they keep the receptor engaged for days rather than minutes. Tirzepatide goes one step further, because it switches on the GLP-1 receptor and also a second incretin receptor called **GIP**. That is why it is described as a dual agonist. ![Diagram of GLP-1 weight-loss injection classes labeled by molecule](https://remevihealth.com/images/molecules/helix-sema.webp) *Semaglutide is a long-acting analog of GLP-1, the incretin hormone the gut releases after eating. The molecule keeps the GLP-1 receptor engaged across the gut, pancreas, and brain far longer than the natural hormone does.* --- ## The names you will see, and what is behind each one Here is the point almost no one explains plainly: behind the many brand names sit just three active ingredients. **Semaglutide.** It is the active ingredient behind two brands. Ozempic is FDA-approved for type 2 diabetes (and to reduce cardiovascular risk in certain adults). Wegovy is FDA-approved for chronic weight management, and also to reduce the risk of major cardiovascular events in adults with cardiovascular disease who have obesity or overweight. One molecule, two brands, different indications. **Tirzepatide.** It is the active ingredient behind Mounjaro, FDA-approved for type 2 diabetes, and Zepbound, FDA-approved for chronic weight management and, more recently, for moderate-to-severe obstructive sleep apnea in adults with obesity. It is the only one of the three that acts on two receptors instead of one. **Liraglutide.** It is the active ingredient behind Saxenda, FDA-approved for chronic weight management. Unlike the others, it is a daily injection. (The brand Victoza uses the same molecule and is approved for type 2 diabetes.) One point of honesty matters here: the compounded preparations of semaglutide or tirzepatide that some clinics offer are not the same as these FDA-approved branded products, and they are not generic versions of them. The footnote at the end of this article spells out that distinction in the exact language it requires. --- ## Semaglutide vs tirzepatide: the difference people ask about most The cleanest way to understand the difference is to count the receptors. Semaglutide activates one, GLP-1. Tirzepatide activates two, GLP-1 and GIP. Almost everything else is shared: the weekly injection, the gradual dose increase, and the gastrointestinal effects early on, because both act on the same GLP-1 pathway. Does that second pathway matter? In trials that compared the two molecules head to head in adults with type 2 diabetes, tirzepatide produced greater average reductions in blood sugar and body weight than semaglutide over the study period. But those are findings from a trial population across a defined window of time, not a forecast for any one person, and individual results vary. Having two receptors does not automatically make tirzepatide the right answer for everyone. The molecule that fits depends on medical history, tolerability, other conditions, cost, and how a body responds to titration. For a side-by-side, our guide to [semaglutide vs tirzepatide, compared](/semaglutide-vs-tirzepatide/) walks through the practical differences. --- ## Injection vs pill, and daily vs weekly Two questions come up almost every time. The first: why are nearly all the potent options injectable? The reason is chemistry. These molecules are peptides, and a swallowed peptide tends to break down in the stomach before it reaches the bloodstream. Subcutaneous delivery sidesteps that problem and lets the molecule last for days. Oral versions exist, but most of the higher-potency options remain injectable for that reason. The second: how often do you take them? Semaglutide and tirzepatide are weekly injections. Liraglutide is daily. None of them starts at the full dose; all begin low and step up slowly over several weeks, which limits the nausea and gastrointestinal discomfort that show up mostly at the start. If you want the mechanism in more depth, [how GLP-1 works in the body](/blog/how-glp1-works/) explains it step by step. And for a broader look at physician-led options, [weight-loss care with a real clinician](/weight-loss/) covers how treatment is actually structured. --- ## How a clinician decides which one to prescribe This is where the list of names stops being the point. Choosing among these injections is not about which one sounds strongest; it is about which one fits your body and your history. A licensed clinician reviews your medical history, current medications, body mass index, metabolic markers, and goals. They weigh expected tolerability, other conditions you have, and cost. Sometimes the right answer is to start with semaglutide; sometimes it is tirzepatide; sometimes it is neither for now. That conversation is exactly the part a prescription alone cannot handle, and it is the work we built [REMEVi's physician-led GLP-1 program](/glp-1/) around: a real clinician on the prescription, a coordinator on the check-ins, and an honest plan rather than a vending machine. The names matter far less than the person reading your specific case. --- ## The science in one line Almost every weight-loss injection you will see (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda) is a long-acting version of the incretin hormones your body already uses to regulate hunger and blood sugar. Knowing the class, GLP-1 with or without GIP, gives you the whole map. What is left is the person who reads your case and chooses with clinical judgment. **Your Health. Your Terms.** Talk to a real clinician at [remevihealth.com](/glp-1/). --- *This article is for general information and does not constitute medical advice. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician. Compounded semaglutide and tirzepatide are non-FDA-approved preparations prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. They are not a generic version of, and are not the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded preparations have not been clinically studied as finished products. Individual results vary. Consult a licensed provider before starting any prescription treatment.*